MA27483A1 - Derives d'azole-pyrimidines fondues - Google Patents

Derives d'azole-pyrimidines fondues

Info

Publication number
MA27483A1
MA27483A1 MA28247A MA28247A MA27483A1 MA 27483 A1 MA27483 A1 MA 27483A1 MA 28247 A MA28247 A MA 28247A MA 28247 A MA28247 A MA 28247A MA 27483 A1 MA27483 A1 MA 27483A1
Authority
MA
Morocco
Prior art keywords
azole
pathologies
disease
pyrimidine derivatives
present
Prior art date
Application number
MA28247A
Other languages
English (en)
Inventor
Mitsuyuki Shimada
Toshiki Murata
Kinji Fuchikami
Hideki Tsujishita
Naoki Omori
Issei Kato
Mami Miura
Klaus Urbahns
Florian Gantner
Kevin Bacon
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of MA27483A1 publication Critical patent/MA27483A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne de nouveaux dérivés d'azole-pyrimidines fondues, des procédés permettant de les préparer et des préparations pharmaceutiques les contenant. Les dérivés d'azole-pyrimidines fondues de la présente invention présentent une capacité renforcée d'inhibition de la phosphotidylinositol-3-kinase (P13K), notamment d'inhibition de la P13K-(gamma) et peuvent s'utiliser pour assurer la prophylaxie et le traitement de pathologies associées à la P13K et en particulier à l'activité de la P13K-(gamma). Les dérivés d'azole de la présente invention s'utilisent plus particulièrement dans le traitement et la prophylaxie des pathologies suivantes : troubles inflammatoires et immunorégulateurs. tels que l'asthme, la dermatite atopique, la rhinite, les maladies allergiques, la maladie pulmonaire obstructive chronique (COPD), le choc septique, les maladies des articulations, les pathologies auto-immunes telles que la polyarthrite rhumatoïde, et la maladie de Graves, le cancer, les troubles de contractilité du myocarde, l'insuffisance cardiaque, le thromboembolisme, l'ischémie et l'athérosclérose. Les composés de la présente invention s'utilisent également pour traiter l'hypertension pulmonaire, l'insuffisance rénale, l'hypertrophie cardiaque, de même que des troubles neurodégénératifs tels que la maladie de Parkinson, la maladie d'Alzheimer, le diabète et l'ischémie focale, ces pathologies se rapportant également à l'activité de la P13K, chez l'homme ou l'animal.
MA28247A 2002-09-30 2005-04-29 Derives d'azole-pyrimidines fondues MA27483A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02021861 2002-09-30

Publications (1)

Publication Number Publication Date
MA27483A1 true MA27483A1 (fr) 2005-08-01

Family

ID=32039115

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28247A MA27483A1 (fr) 2002-09-30 2005-04-29 Derives d'azole-pyrimidines fondues

Country Status (33)

Country Link
US (2) US7511041B2 (fr)
EP (2) EP2042504B1 (fr)
JP (1) JP4790266B2 (fr)
KR (1) KR101059652B1 (fr)
CN (1) CN100384846C (fr)
AR (2) AR041426A1 (fr)
AT (2) ATE511510T1 (fr)
AU (1) AU2003293310B2 (fr)
BR (1) BRPI0314830B8 (fr)
CA (1) CA2499134C (fr)
CY (2) CY1109790T1 (fr)
DE (1) DE60324296D1 (fr)
DK (2) DK2042504T3 (fr)
EC (2) ECSP055768A (fr)
ES (2) ES2367141T3 (fr)
HK (1) HK1084393A1 (fr)
HR (2) HRP20050375B1 (fr)
IL (1) IL166855A (fr)
MA (1) MA27483A1 (fr)
MX (1) MXPA05001808A (fr)
MY (1) MY140756A (fr)
NO (1) NO331457B1 (fr)
NZ (1) NZ539062A (fr)
PE (1) PE20050089A1 (fr)
PL (1) PL226562B1 (fr)
PT (2) PT1549652E (fr)
RU (1) RU2326881C9 (fr)
SI (2) SI2042504T1 (fr)
TW (1) TWI327570B (fr)
UA (1) UA82205C2 (fr)
UY (1) UY28001A1 (fr)
WO (1) WO2004029055A1 (fr)
ZA (1) ZA200503306B (fr)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
CN102976984B (zh) 2003-08-29 2015-04-08 三井化学株式会社 农园艺用杀虫剂的制备中间体
ES2605792T3 (es) 2004-05-13 2017-03-16 Icos Corporation Quinazolinona usada como inhibidor de la fosfatidilinositol 3-quinasa delta humana
CA2579279C (fr) 2004-10-07 2013-10-01 Boehringer Ingelheim International Gmbh Derives de thiazole tricyclique en tant que pi3-kinases
WO2006040645A1 (fr) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited Derives de benzamide n-(3,5-dichloropyridine-4-yle)-2,4,5-alcoxy et 2,3,4 alcoxy en tant qu'inhibiteurs de pde-iv (phosphodiesterase de type iv) pour traiter des maladies inflammatoires telles que l'asthme
US20100035244A1 (en) 2005-04-14 2010-02-11 The Trustees Of Boston University Diagnostic for lung disorders using class prediction
CN101233119A (zh) * 2005-07-29 2008-07-30 4Sc股份有限公司 新型杂环NF-κB抑制剂
EP1999472A2 (fr) 2006-03-09 2008-12-10 The Trustees Of Boston University Méthodes de diagnostic et de pronostic pour troubles des poumons utilisant des profils d'expression de gènes de cellules épithéliales nasales
US7517995B2 (en) 2006-04-06 2009-04-14 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-cyclopentapyrazole
US7691868B2 (en) 2006-04-06 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline
AU2007243457B2 (en) * 2006-04-26 2012-02-23 F. Hoffmann-La Roche Ag Pharmaceutical compounds
WO2008064244A2 (fr) * 2006-11-20 2008-05-29 The Trustees Of Columbia University In The City Of New York Modulation des phosphoinositides pour le traitement de maladies neurodégénératives
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EP1953163A1 (fr) * 2007-02-01 2008-08-06 Boehringer Ingelheim Pharma GmbH & Co. KG Dérivés de Pteridinone comme inhibiteurs des Kinases PI3
WO2008148023A2 (fr) * 2007-05-23 2008-12-04 Medical College Of Georgia Research Institute, Inc. Compositions et procédés pour traiter des troubles neurologiques
WO2009039140A1 (fr) * 2007-09-17 2009-03-26 Smithkline Beecham Corporation Dérivés de pyridopyrimidine en tant qu'inhibiteurs de kinase p13
CN101990577A (zh) 2007-09-19 2011-03-23 波士顿大学理事会 鉴定肺病药物开发的新途径
CA2713388C (fr) * 2008-01-14 2016-03-29 William Scott Derives de 2,3-dihydroimidazo [1,2-c] quinazoline a substitution sulfone utilises pour traiter des troubles hyperproliferants et des maladies associees a l'angiogenese
WO2009094224A1 (fr) 2008-01-25 2009-07-30 Millennium Pharmaceuticals, Inc. Thiophènes et leurs utilisations
WO2009111547A1 (fr) * 2008-03-04 2009-09-11 Wyeth Composés de 7h-pyrrolo[2,3-h]quinazoline, leur utilisation comme inhibiteurs de la mtor kinase et de la pi3-kinase, et leur synthèse
JPWO2009128520A1 (ja) * 2008-04-18 2011-08-04 塩野義製薬株式会社 Ｐｉ３ｋ阻害活性を有する複素環化合物
WO2009155527A2 (fr) * 2008-06-19 2009-12-23 Progenics Pharmaceuticals, Inc. Inhibiteurs de phosphatidylinositol 3 kinase
EP2168582A1 (fr) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Combinaisons de 2,3-dihydroimidazo[1,2-c]quinazolines substituées
EP2168583A1 (fr) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Utilisation de 2,3-dihydroimidazo[1,2-c]quinazolines substituées pour le traitement du myélome
WO2010038165A1 (fr) * 2008-09-30 2010-04-08 Pfizer Inc. Composés d'imidazo[1,5]naphtyridine, leur utilisation pharmaceutique et compositions associées
DK2364983T3 (da) * 2008-11-11 2013-12-09 Jeil Pharmaceutical Co Ltd Nyt tricyklisk derivat eller farmaceutisk acceptable salte deraf, fremgangsmåde til fremstilling deraf og farmaceutisk sammensætning indeholdende disse
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
WO2010057048A1 (fr) 2008-11-13 2010-05-20 Calistoga Pharmaceuticals Inc. Thérapies pour tumeurs malignes hématologiques
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
CN102395585A (zh) 2009-01-30 2012-03-28 米伦纽姆医药公司 杂芳基化合物和其作为pi3k抑制剂的用途
CN102439012A (zh) 2009-03-24 2012-05-02 吉里德卡利斯托加公司 2-嘌呤基-3-甲苯基-喹唑啉酮衍生物的阻转异构体和使用方法
KR20120005523A (ko) 2009-04-20 2012-01-16 길리아드 칼리스토가 엘엘씨 고형 종양의 치료 방법
KR101771193B1 (ko) * 2009-04-30 2017-09-05 글락소 그룹 리미티드 Ｐｉ3­키나아제 억제제로서 옥사졸 치환된 인다졸
AU2010276160A1 (en) 2009-07-21 2012-02-09 Gilead Calistoga Llc Treatment of liver disorders with PI3K inhibitors
RU2595718C2 (ru) * 2009-09-09 2016-08-27 Селджен Авиломикс Рисерч,Инк. Ингибиторы pi3-киназы и их применение
CA2796253A1 (fr) * 2010-04-16 2011-10-20 Bayer Intellectual Property Gmbh Combinaisons contenant une 2,3-dihydroimidazo[1,2-c]quinazoline substituee
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9381177B2 (en) 2010-10-01 2016-07-05 Bayer Intellectual Property Gmbh Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
EP2638043B1 (fr) * 2010-11-11 2017-06-07 Bayer Intellectual Property GmbH 2,3-dihydroimidazo[1,2-c]quinolines à substitution arylaminoalcool
EP2638044B1 (fr) 2010-11-11 2017-08-30 Bayer Intellectual Property GmbH 2,3-dihydroimidazo[1,2-c]quinazolines à substitution alcoxy
UA113280C2 (xx) * 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EP2508525A1 (fr) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Sels de 2,3-dihydroimidazo[1,2-C]quinazoline substitutés
ES2848273T3 (es) 2012-03-05 2021-08-06 Gilead Calistoga Llc Formas polimórficas de (S)-2-(1-(9H-purin-6-ilamino)propilo)-5-fluoro-3-fenilquinazolina-4(3H)-ona
EP3626308A1 (fr) 2013-03-14 2020-03-25 Veracyte, Inc. Procédés d'évaluation de l'état d'une maladie pulmonaire obstructive chronique (copd)
JP2016520528A (ja) 2013-03-15 2016-07-14 ジェネンテック， インコーポレイテッド 癌の治療及び抗癌剤耐性の防止方法
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
CU24400B1 (es) 2013-04-08 2019-04-04 Bayer Pharma AG Una composición que comprende 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas
KR102002265B1 (ko) 2013-05-01 2019-07-19 에프. 호프만-라 로슈 아게 바이헤테로아릴 화합물 및 이의 용도
WO2015027431A1 (fr) 2013-08-29 2015-03-05 Merck Sharp & Dohme Corp. Antagonistes 2,2-difluorodioxolo du récepteur a2a
SG11201604825VA (en) 2013-12-20 2016-07-28 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
AU2014364414A1 (en) 2013-12-20 2016-06-30 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (S) -2-(1-(9H-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3H) -one
KR20170012560A (ko) 2014-06-13 2017-02-02 길리애드 사이언시즈, 인코포레이티드 포스파티딜이노시톨 3-키나제 억제제
WO2016073768A1 (fr) 2014-11-05 2016-05-12 Veracyte, Inc. Systèmes et procédés de diagnostic de la fibrose pulmonaire idiopathique sur des biopsies transbronchiques à l'aide de l'apprentissage automatique et de données de transcription dimensionnelle élevée
EP3018127A1 (fr) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthèse de copanlisib et son sel de dichlorhydrate
EP3018131A1 (fr) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthèse de copanlisib et son sel de dichlorhydrate
EP3268490B1 (fr) 2015-03-09 2020-07-08 Bayer Pharma Aktiengesellschaft Combinaisons contenant des 2,3-dihydroimidazo[1,2-c]quinazoline substituées
CN105130998B (zh) * 2015-09-25 2017-07-28 苏州立新制药有限公司 库潘尼西的制备方法
CN105130997B (zh) * 2015-09-25 2017-12-05 苏州明锐医药科技有限公司 一种库潘尼西的制备方法
CN108884098B (zh) * 2016-03-08 2021-09-14 拜耳制药股份公司 2-氨基-N-[7-甲氧基-2,3-二氢咪唑并[1,2-c]喹唑啉-5-基]嘧啶-5-甲酰胺类
EP3219329A1 (fr) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinaisons de copanlisib
US10927417B2 (en) 2016-07-08 2021-02-23 Trustees Of Boston University Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions
WO2018054782A1 (fr) 2016-09-23 2018-03-29 Bayer Pharma Aktiengesellschaft Combinaison d'inhibiteurs de la pi3k
WO2018112176A1 (fr) 2016-12-14 2018-06-21 Tarveda Therapeutics, Inc. Conjugués ciblant hsp90 et formulations de ces derniers
CA3054249A1 (fr) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combinaisons de copanlisib avec un anticorps anti-pd-1
EP3645005A1 (fr) 2017-06-28 2020-05-06 Bayer Consumer Care AG Combinaison d'un inhibiteur de pi3k et d'un antagoniste du récepteur des androgènes
PL3678644T3 (pl) 2017-09-08 2023-09-11 Bayer Pharma Aktiengesellschaft Formulacje kopanlizybu
EP3498266A1 (fr) 2017-12-15 2019-06-19 Bayer Consumer Care AG Formulations de copanlisib
MX2020003126A (es) * 2017-09-20 2020-10-01 Abm Therapeutics Corp Derivados de iminopirimidina ciclicos como inhibidores de cinasa.
WO2019073031A1 (fr) 2017-10-13 2019-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Polythérapie du cancer du pancréas
EP3713963A1 (fr) 2017-11-23 2020-09-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Nouveau marqueur permettant de prédire la sensibilité à des inhibiteurs de pi3k
WO2019105734A1 (fr) 2017-11-28 2019-06-06 Bayer Consumer Care Ag Combinaisons de copanlisib
WO2019105835A1 (fr) 2017-11-29 2019-06-06 Bayer Consumer Care Ag Combinaisons de copanlisib et d'anetumab ravtansine
WO2019197269A1 (fr) 2018-04-11 2019-10-17 Bayer Aktiengesellschaft Combinaisons de copanlisib et de dérivés de triazolone ainsi que leur utilisation dans le traitement du cancer
WO2020020385A1 (fr) * 2018-07-27 2020-01-30 上海翰森生物医药科技有限公司 Inhibiteur de dérivé tricyclique, son procédé de préparation et application
CN109053554B (zh) * 2018-08-01 2020-07-28 江苏八巨药业有限公司 一种使用催化剂合成3-乙酰吡啶的方法
CA3110754A1 (fr) 2018-08-28 2020-03-05 Bayer As Combinaison d'inhibiteurs de pi3k et de conjugues de thorium cibles
WO2020078788A1 (fr) 2018-10-16 2020-04-23 Bayer Aktiengesellschaft Combinaison d'inhibiteurs de kinase atr avec des composés de 2,3-dihydro-imidazo[1,2-c]quinazoline
EP3877511A1 (fr) 2018-11-05 2021-09-15 Iovance Biotherapeutics, Inc. Expansion de til utilisant des inhibiteurs de la voie akt
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
WO2020164997A1 (fr) 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combinaison d'inhibiteurs de la pi3k
CN114621236B (zh) * 2022-04-25 2024-06-18 河南湾流生物科技有限公司 一种喹啉类饲料添加剂的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644354A (en) 1968-09-16 1972-02-22 Sandoz Ag 5-substituted-2 3-dihydroimidazo(1 2-c)quinazolines
US4287341A (en) 1979-11-01 1981-09-01 Pfizer Inc. Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
CN1033644C (zh) * 1993-01-02 1996-12-25 瑞安大药厂股份有限公司 3-取代甲基-2，3-二氢咪唑并[1，2-c]喹唑啉衍生物，其制备与用途
WO1996004923A1 (fr) 1994-08-12 1996-02-22 Pro-Neuron, Inc. Procedes permettant de traiter la sepsie ou des maladies inflammatoires avec des nucleosides a base d'oxypurine
US6066642A (en) * 1996-01-29 2000-05-23 The United States Of America As Represented By The Department Of Health And Human Services Dihydropyridine-, pyridine-, benzopyran-4-one- and triazoloquinazoline derivative, their preparation and their use as adenosine receptor antagonists
US5932584A (en) * 1997-05-06 1999-08-03 National Science Council Optically active 2,3-dihydroimidazo(1,2-C) quinazoline derivatives, the preparation and antihypertensive use thereof
MXPA02010618A (es) 2000-04-25 2004-05-05 Icos Corp Inhibidores de fosfatidilinositol 3-quinasa delta.
WO2001083456A1 (fr) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Derives d'heteroaryle condenses

Also Published As

Publication number Publication date
AU2003293310B2 (en) 2010-04-01
MXPA05001808A (es) 2005-08-16
US20060128732A1 (en) 2006-06-15
ATE411996T1 (de) 2008-11-15
PT2042504E (pt) 2011-09-07
WO2004029055A1 (fr) 2004-04-08
KR101059652B1 (ko) 2011-08-25
DK2042504T3 (da) 2011-09-19
HRP20131159B1 (hr) 2019-11-01
ECSP055768A (es) 2005-08-11
ECSP11005768A (es) 2011-03-31
ES2367141T3 (es) 2011-10-28
CA2499134C (fr) 2011-12-20
IL166855A (en) 2014-05-28
AR072458A2 (es) 2010-09-01
PE20050089A1 (es) 2005-04-20
TWI327570B (en) 2010-07-21
NO331457B1 (no) 2012-01-09
US8129386B2 (en) 2012-03-06
NO20052076L (no) 2005-04-27
PL226562B1 (pl) 2017-08-31
MY140756A (en) 2010-01-15
AU2003293310A1 (en) 2004-04-19
HRP20050375A2 (en) 2006-05-31
EP1549652A1 (fr) 2005-07-06
SI2042504T1 (sl) 2011-10-28
CA2499134A1 (fr) 2004-04-08
EP2042504A1 (fr) 2009-04-01
ES2312843T3 (es) 2009-03-01
HRP20050375B1 (hr) 2014-03-14
UA82205C2 (en) 2008-03-25
BRPI0314830B1 (pt) 2018-03-27
BRPI0314830B8 (pt) 2021-05-25
PT1549652E (pt) 2008-12-15
KR20050067404A (ko) 2005-07-01
CN100384846C (zh) 2008-04-30
PL375935A1 (en) 2005-12-12
US7511041B2 (en) 2009-03-31
JP4790266B2 (ja) 2011-10-12
RU2005113165A (ru) 2005-10-10
HK1084393A1 (en) 2006-07-28
ATE511510T1 (de) 2011-06-15
EP2042504B1 (fr) 2011-06-01
US20090270388A1 (en) 2009-10-29
ZA200503306B (en) 2006-07-26
DK1549652T3 (da) 2009-02-23
JP2006508063A (ja) 2006-03-09
HRP20131159A2 (hr) 2014-05-23
RU2326881C2 (ru) 2008-06-20
UY28001A1 (es) 2004-04-30
CN1688582A (zh) 2005-10-26
CY1109790T1 (el) 2014-09-10
RU2326881C9 (ru) 2009-04-10
NZ539062A (en) 2007-05-31
TW200413379A (en) 2004-08-01
EP1549652B1 (fr) 2008-10-22
DE60324296D1 (de) 2008-12-04
CY1112174T1 (el) 2015-12-09
AR041426A1 (es) 2005-05-18
SI1549652T1 (sl) 2009-04-30
BR0314830A (pt) 2005-08-16

Similar Documents

Publication Publication Date Title
MA27483A1 (fr) Derives d'azole-pyrimidines fondues
MXPA04004019A (es) Derivados de pirimido?4,5-b?indol.
MA30318B1 (fr) Composes de sulfonamide de pyrimidinyle inhibant l'adhesion leucocytaire mediee par vla-4
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
ATE187447T1 (de) 3-phenyl-2-isoxazoline derivate als entzündugshemmende mittel
TNSN04111A1 (fr) Derives de quinazoline pour le traitement d'une croissance cellulaire anormale
Nandakishore et al. Selective cyclooxygenase inhibitors: current status
MA27491A1 (fr) Derives de phenyl-ou heteroarylamino-alcanes comme antagonistes ou recepteur ip
MA24694A1 (fr) Derives de thienopyrimidine et thienopyridine utiles comme agents anticancereux, et compositions les contenant.
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
ES2104424T3 (es) Compuestos de isoxazolina como agentes antiinflamatorios.
MA33772B1 (fr) Dérivés d'acide carboxylique cyclique substitué par acylamino et leur utilisation en tant qu'agents pharmaceutiques
MA31862B1 (fr) Anticorps anti-mésothéline et leurs utilisations
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
Cougnoux et al. Necroptosis inhibition as a therapy for Niemann-Pick disease, type C1: Inhibition of RIP kinases and combination therapy with 2-hydroxypropyl-β-cyclodextrin
MA31397B1 (fr) Sels de [4(-(6-fluoro-7-méthylamino-2, 4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phényl]-5-chloro-thiophén-2-yl-sulfonylurée, formes et procédés qui leur sont associés
MA35567B1 (fr) Nouvelle formulation de méloxicam
MA32798B1 (fr) Acides naphtylacétiques
EA200500172A1 (ru) Азабициклопроизводные в качестве антагонистов мускариновых рецепторов
JP2010248224A (ja) 治療又は予防薬
MA33602B1 (fr) Composition pharmaceutique permettant de prévenir ou de traiter l'arthrite rhumatoïde, contenant du rébamipide
MA27690A1 (fr) Composition pharmaceutique androgene et procede pour le traitement de la depression.
MA44018B1 (fr) Dérivés de tétrahydroisoquinoline
WO2021177332A1 (fr) Inhibiteur d'inflammasome nlrp3 et composition pharmaceutique de prévention ou de traitement d'une maladie inflammatoire
JP2006502113A (ja) マトリックス・メタロプロテイナーゼ−１３アロステリック阻害剤と、セレコキシブ又はバルデコキシブでないシクロオキシゲナーゼ−２選択的阻害剤との複合体